A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University Health Network, Toronto
Children's Oncology Group
University of Southern California
National Cancer Institute (NCI)
Seattle Children's Hospital
GlaxoSmithKline
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Valo Therapeutics Oy
Stanford University
Children's National Research Institute
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
BioEclipse Therapeutics
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
St. Jude Children's Research Hospital
Celgene
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
St. Jude Children's Research Hospital
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Novartis
City of Hope Medical Center
Children's Oncology Group
Children's Oncology Group
INSYS Therapeutics Inc
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center